AAAAAA

   
Results: 1-7 |
Results: 7
Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012)
Authors: Eshleman, SH Mracna, M Guay, LA Deseyve, M Cunningham, S Mirochnick, M Musoke, P Fleming, T Fowler, MG Mofenson, LM Mmiro, F Jackson, JB
Citation: Sh. Eshleman et al., Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012), AIDS, 15(15), 2001, pp. 1951-1957
Impact of human immunodeficiency virus type 1 (HIV-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent HIV-1 vertical transmission (HIV Network for Prevention Trials 012 study)
Authors: Eshleman, SH Becker-Pergola, G Deseyve, M Guay, LA Mracna, M Fleming, T Cunningham, S Musoke, P Mmiro, F Jackson, JB
Citation: Sh. Eshleman et al., Impact of human immunodeficiency virus type 1 (HIV-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent HIV-1 vertical transmission (HIV Network for Prevention Trials 012 study), J INFEC DIS, 184(7), 2001, pp. 914-917
Identification of the K103N resistance mutation in Ugandan women receivingnevirapine to prevent HIV-1 vertical transmission
Authors: Jackson, JB Becker-Pergola, G Guay, LA Musoke, P Mracna, M Fowler, MG Mofenson, LM Mirochnick, M Mmiro, F Eshleman, SH
Citation: Jb. Jackson et al., Identification of the K103N resistance mutation in Ugandan women receivingnevirapine to prevent HIV-1 vertical transmission, AIDS, 14(11), 2000, pp. F111-F115
A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006)
Authors: Musoke, P Guay, LA Bagenda, D Mirochnick, M Nakabiito, C Fleming, T Elliott, T Horton, S Dransfield, K Pav, JW Murarka, A Allen, M Fowler, MG Mofenson, L Hom, D Mmiro, F Jackson, JB
Citation: P. Musoke et al., A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006), AIDS, 13(4), 1999, pp. 479-486
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVMET 012 randomised trial
Authors: Guay, LA Musoke, P Fleming, T Bagenda, D Allen, M Nakabiito, C Sherman, J Bakaki, P Ducar, C Deseyve, M Emel, L Mirochnick, M Fowler, MG Mofenson, L Miotti, P Dransfield, K Bray, D Mmiro, F Jackson, JB
Citation: La. Guay et al., Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVMET 012 randomised trial, LANCET, 354(9181), 1999, pp. 795-802
Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa
Authors: Marseille, E Kahn, JG Mmiro, F Guay, L Musoke, P Fowler, MG Jackson, JB
Citation: E. Marseille et al., Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa, LANCET, 354(9181), 1999, pp. 803-809
Human immunodeficiency virus status and delayed-type hypersensitivity skintesting in Ugandan children
Authors: Mandalakas, AM Guay, L Musoke, P Carroll-Pankhurst, C Olness, KN
Citation: Am. Mandalakas et al., Human immunodeficiency virus status and delayed-type hypersensitivity skintesting in Ugandan children, PEDIATRICS, 103(2), 1999, pp. E211-E217
Risultati: 1-7 |